Immunotherapy for Alzheimer disease: The promise and the problem

Archives of Neurology

Volumn 62, Issue 10, 2005, Pages 1506-1507

  Rosenberg, Roger N ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE;

ALZHEIMER DISEASE; ANTIBODY RESPONSE; CYTOTOXIC T LYMPHOCYTE; EDITORIAL; GENE THERAPY; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MENINGOENCEPHALITIS; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; ENCEPHALITIS; GENE EXPRESSION; GENETIC PREDISPOSITION TO DISEASE; IMMUNOTHERAPY;

EID: 26444606932     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.62.10.1506     Document Type: Editorial

References (14)

1. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400:173-177.
2. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995;373:523-527.
3. Morgan D, Diamond DM, Gottschall PE, et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer disease. Nature. 2000;408:982-985.
4. Janus C, Pearson J, McLaurin J, et al. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer disease. Nature. 2000;408:979-982.
5. Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology. 2005;64:94-101.
6. Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a sub-set of patients with AD after Abeta42 immunization. Neurology. 2003;61:46-54.
7. Fox NC, Black RS, Gilman S, et al. Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005;64:1563-1572.
8. Gilman S, Koller M, Black RS, et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005;64:1553-1562.
9. (1-42) Immunotherapy in preimmunization gene expression patterns of blood cells. Arch Neurol. 2005;62:1531-1536.
10. Salvador J, Adams EJ, Ershler R, Ershler WB. Future challenges in analysis and treatment of human immune senescence. Immunol Allergy Clin North Am. 2003;23:133-148.
11. Arreaza EE, Gibbons JJ Jr, Siskind GW, Weksler ME. Lower antibody response to tetanus toxoid associated with higher auto-anti-idiotypic antibody in old compared with young humans. Clin Exp Immunol. 1993;92:169-173.
12. Looney RJ, Hasan MS, Coffin D, et al. Hepatitis B immunization of healthy elderly adults: relationship between naive CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol. 2001;21:30-36.
13. Schenk DB, Seubert P, Lieberburg I, Wallace J. Beta-peptide immunization: a possible new treatment for Alzheimer disease. Arch Neurol. 2000;57:934-936.
14. Qu B, Rosenberg RN, Li L, Boyer PJ, Johnston SA. Gene vaccination to bias the immune response to amyloid-β peptide as therapy for Alzheimer disease. Arch Neurol. 2004;61:1859-1864.